Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) Shares Outstanding (Diluted Average) (2016 - 2025)

Regenxbio has reported Shares Outstanding (Diluted Average) over the past 10 years, most recently at $51.6 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Diluted Average) at $51.6 million for Q4 2025, up 4.17% from a year ago — trailing twelve months through Dec 2025 was $51.6 million (up 4.17% YoY), and the annual figure for FY2025 was $51.6 million, up 4.17%.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $51.6 million at Regenxbio, roughly flat from $51.7 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for RGNX hit a ceiling of $51.7 million in Q3 2025 and a floor of $42510.0 in Q2 2021.
  • Median Shares Outstanding (Diluted Average) over the past 5 years was $43.9 million (2021), compared with a mean of $34.8 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): plummeted 99.89% in 2021 and later surged 101853.46% in 2023.
  • Regenxbio's Shares Outstanding (Diluted Average) stood at $43.9 million in 2021, then dropped by 1.73% to $43.2 million in 2022, then increased by 1.35% to $43.7 million in 2023, then rose by 13.2% to $49.5 million in 2024, then grew by 4.17% to $51.6 million in 2025.
  • The last three reported values for Shares Outstanding (Diluted Average) were $51.6 million (Q4 2025), $51.7 million (Q3 2025), and $51.5 million (Q2 2025) per Business Quant data.